Dietary topoisomerase II-poisons by Tanner, Berno et al.
EXCLI Journal 2002;1:8-14 (ISSN 1611-2156) 
received: 19. December 2002, accepted: 29. December 2002, published: 30. December 2002 
 
Review: 
 
Dietary topoisomerase II-poisons: contribution of soy products to infant 
leukemia? 
 
Jan G. Hengstler*, Carolin K. Heimerdinger1, Ilka B. Schiffer1, Susanne Gebhard1, Jens 
Sagemüller1, Berno Tanner2, Hermann M. Bolt3, Franz Oesch1 
 
Institute of Legal Medicine, Department of Molecular Toxicology, University of Leipzig, 
Johannisallee 28, 04103 Leipzig, Germany, Telephone: 0049 6131 231721, Fax: 0049 6131 
230506, E-mail: hengstle@mail.Uni-Mainz.de; 1Institute of Toxicology and 2Department of 
Gynecology, University of Mainz, Obere Zahlbacher Str. 67, 55131 Mainz, Germany, 
3Institute of Occupational Physiology at the University of Dortmund; Ardeystraße 67, D-
44139 Dortmund, Germany (*corresponding author) 
 
 
ABSTRACT 
 
DNA topoisomerases are nuclear enzymes inducing transient breaks in the DNA allowing 
DNA strands or double helices to pass through each other. The clinically used DNA 
topoisomerase II-poison etoposide is known to induce DNA double strand breaks leading to 
chromosomal aberrations and leukemias. Recently, some alarming studies have been 
published, suggesting that maternal exposure to low doses of dietary topoisomerase II-
poisons, including bioflavonoids such as genistein or quercetin, may contribute to the 
development of infant leukemia: approximately 80% of infants with acute myelogenous 
leukemia (AML) and acute lymphoblastic leukemia (ALL) have chromosome translocations 
involving the MLL (mixed lineage leukemia) gene. It has been shown that antineoplastic 
chemotherapy with the leukemogenic topoisomerase II-poison etoposide induced identical 
chromosomal aberrations involving the MLL gene compared to children with infant leukemia. 
Interestingly, the MLL cleavage sites induced by etoposide colocalized with the cleavage sites 
observed in infant leukemia. In addition, an almost 10-fold higher risk of infant AML has 
been reported for mothers consuming relatively high levels of topoisomerase II-poison 
containing foods. These observations are relevant, since many foods contain topoisomerase II-
poisons, predominantly soy and soy products, but also coffee, wine, tea, cocao, as well as 
some fruits and vegetables. Further studies on the role of dietary topoisomerase II-poisons are 
urgently required. If the causal relationship between dietary exposure to topoisomerase II-
poisons and infant leukemia will be confirmed, care should be taken to reduce exposure to 
critical foods during pregnancy. 
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INTRODUCTION 
 
Due to the periods of rapid cell turnover it is 
likely that fetal tissues or tissues of children 
are more susceptible to some environmental 
or dietary genotoxic agents (Hengstler et al., 
1998, 1999a; von Mach, 2002). Recently, 
some studies suggested a causal relationship 
between infant leukemia induced in utero 
and maternal exposure to dietary 
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bioflavonoids - that besides many other 
effects, especially those as endocrine 
disruptors (Degen and Bolt, 2000), also act as 
topoisomerase II-poisons (Ross, 2000; Strick 
et al., 2000; Alexander et al., 2001; 
McDonald et al., 2001; Abe, 1999). In 
contrast to infant leukemia no role of dietary 
topoisomerase II-poisons has been observed 
in pathogenesis of adult leukemia. The 
majority of studies reported beneficial effects 
of dietary bioflavonoids for adult individuals. 
Several epidemiological studies observed a 
decreased risk for prostate, breast, uterus, 
colon and lung cancer for adults consuming 
high levels of bioflavonoids. Numerous 
mechanisms have been reported that may 
explain these protective effects including 
inhibition of tyrosine kinases, anti-estrogenic 
effects, release of transforming growth factor 
beta, induction of apoptosis and antioxidative 
effects. One of the main sources of dietary 
flavonoids are soy beans and soy products 
(Fig. 1; Table 1). Soy products, including for 
instance soy burgers, soy hot digs, soy 
cheese, etc., have proliferated due to the 
labelling of soy as a food that reduces the 
risk of some tumor types and also the risk of 
heart disease. Exposures to dietary 
isoflavones have been reported to range 
between 50 and 100 mg/day in East Asian 
populations resulting in plasma 
concentrations of 40-240 ng/ml daidzein and 
genistein (combined) (Bolt et al., 2000). In 
European populations dietary exposures to 
isoflavones are much lower usually not 
exceeding 1 mg/day. However, the 
consequences of exposure to bioflavonoids 
may differ between adults and 
transplacentally exposed embryos. Due to the 
rapid cell proliferation the aspect of 
topoisomerase II inhibition by bioflavonoids 
may be much more critical for embryos than 
for adults. 
 
In this review, we report about the 
mechanisms of action of topoisomerase II-
poisons, carcinogenic effects of the latter and 
discuss some recent studies suggesting that 
dietary exposure to topoisomerase II-poisons 
may have a causative role in infant leukemia.   
 
 
MECHANISM OF ACTION OF 
TOPOISOMERASE II AND 
INHIBITORS 
 
DNA topoisomerases are nuclear enzymes, 
which induce transient breaks in the DNA 
allowing DNA strands or double helices to 
pass through each other (Toonen and Hande, 
2001; Wang, 2002; Hengstler et al., 1999b). 
By this action topoisomerases solve 
topological problems of DNA in replication, 
transcription, recombination and 
chromosome condensation as well as 
decondensation. DNA topoisomerases fall 
into two major classes: the type I enzymes 
that induce single stranded cuts in DNA, and 
the type II enzymes that cut and pass double 
stranded DNA.  
 
The mechanism of action of topoisomerase II 
can be dissected into a series of steps 
initiated by the binding of DNA to both 
subunits (S1 and S2) of the enzyme (Fig. 
2A). In the next step, topoisomerase II 
cleaves the DNA, forming a phosphotyrosine 
linkage between each DNA single strand 
break product and the catalytic tyrosines of 
both topoisomerase II subunits (Fig 2B). The 
latter step depends on the presence of 
magnesium. In a next ATP-dependent step, 
topoisomerase II traps a second DNA double 
strand (Fig. 2C). Trapping of the second 
DNA douplex is achieved by a 
conformational change of the N-terminal 
domains of both subunits, leading to a closed 
clamp. After trapping of the second DNA 
double strand (termed trans- or T-strand) it 
will pass the gap of the first DNA double 
strand (termed gap- or G-strand) (Fig. 2D). 
As soon as the T-strand has passed the G-
strand the carboxy terminal portion of the 
enzyme undergoes a conformational change 
(Fig. 2E) that allows the exit of the T-strand 
(Fig. 2F). In a next step topoisomerase II 
reverses the cleavage reaction of the G-strand 
(Fig. 2G). After religation of the G-strand 
hydrolysis of ATP leads to a conformational 
change of the N-terminal part of both 
subunits of topoisomerase II that allows 
dissociation of the G-strand (Fig. 2H).  
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 Fig. 1: Soy products: as a rich source
of isoflavones soy has been reported
to reduce coronary heart disease and
cancer risk in exposed adults.
However, some recent studies provide
evidence that transplacental exposure
of embryos to isoflavones may
contribute to infant leukemia. 
 
 
The “classical” topoisomerase II targeting 
substances act by trapping the cleaved G-
strand-enzyme intermediate, thus, blocking 
religation and enzyme release, leaving the 
DNA with a permanent double strand break. 
These substances that lead to higher levels of 
covalent topoisomerase II-DNA complexes 
have been termed topoisomerase II-
“poisons”, whereas substances that inhibit 
the enzyme during other steps are referred to 
as “catalytic inhibitors” (Walker and Nitiss, 
2002). The best known topoisomerase II-
poisons belong to two classes of 
antineoplastic agents, the 
epipodophyllotoxins (e.g. etoposide and 
teniposide) and the anthracyclines (e.g. 
doxorubicin). Catalytic inhibitors include for 
instance derivatives of coumarin antibiotics, 
such as the coumermycins and novobiocin, 
the thiobarbiturate merbarone and the 
bisdioxopiperazines (Walker and Nitiss, 
2002). However, besides the mentioned 
drugs there is a relatively large number of 
natural and synthetic products present in 
environment and food that act as 
topoisomerase II-poisons and/or catalytic 
inhibitors (Table 1). 
 
CARCINOGENICITY OF 
TOPOISOMERASE II-POISONS 
 
DNA double strand breaks induced by 
topoisomerase II-poisons can induce 
apoptosis of tumor cells contributing to the 
therapeutic effects of epipodophyllotoxins 
and anthracyclins (Walker and Nitiss, 2002). 
In addition, the presence of covalent 
topoisomerase II-DNA complexes arrests the 
replication fork, which also contributes to the 
antineoplastic effects. However, if healthy 
cells survive exposure to topoisomerase II-
poisons DNA double strands may lead to 
chromosomal aberrations. The best studied 
chromosomal aberrations induced by 
topoisomerase II-inhibitors in humans are 
translocations involving the MLL gene 
located at chromosome 11q23. After 
exposure to etoposide or doxorubicin MLL is 
rearranged with partner genes in at least 40 
different translocations the most common 
being translocations with chromosomes 4, 6 
and 9 (Strick et al., 2000). The latter 
translocations are frequently observed in 
patients that have been treated with etoposide 
and teniposide and developed therapy-related 
acute myeloid leukemias (AML). There is no 
doubt that the topoisomerase II-poison 
etoposide is carcinogenic in humans. AML 
develops relatively early after etoposide 
therapy (2-3 years). Cumulative etoposide 
doses of 2 to 3 g/m2 body surface are 
associated with a cumulated 6-year risk for 
development of secondary leukemia of 2.2 % 
(Toonen and Hande, 2001). For patients 
receiving less than 2 g/m2 etoposide a 0.4-0.6 
% risk was found.  
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Table 1: Topoisomerase II-poisons and/or catalytic inhibitors in environment and food. 
 
Substance    Sources of human exposure 
 
Flavonoids 
 Quercetin   Fruits and vegetables 
 Genistein   Soy 
 TTIG-2535   Investigational soy drug product 
 
Catechins    Tea, wine, chocolate 
 
Caffeine     Coffee, tea 
 
Thiram     Agricultural fungicide 
 
Benzene metabolites   Gasoline stations 
 p-Benzoquinone 
 Hydroquinone 
 Catechol 
 4,4’-Biphenol 
 
Senna     Anthraquinone laxative 
 
Dipyrone, Baygon, Thiram  Insecticides 
   
 
 
 
In conclusion, exposures to high doses of 
topoisomerase II-poisons in cancer therapy 
have clearly shown that topoisomerase II-
poisons induce chromosomal translocations 
and leukemia. 
 
 
DIETARY EXPOSURE TO 
TOPOISOMERASE II-POISONS: ROLE 
IN INFANT LEUKEMIA 
 
The carcinogenicity of high doses of 
etoposide and the fact that humans are 
exposed to low doses of several 
topoisomerase II-poisons in food (Table 1) 
led to concern that exposure to these 
substances may contribute to carcinogenesis 
in the general population. In this context the 
question whether carcinogenic topoisomerase 
II-poisons act by threshold or non-threshold 
mechanisms is of high relevance (Hengstler 
et al., 2003). At a first glance one might 
expect that carcinogens that act by inhibition 
of enzymes have thresholds (von Mach et al., 
2002; von Mach et al., 2003). This may be 
true for inhibitors of detoxifying enzymes or 
some DNA repair enzymes, where low doses 
of inhibitors will be without consequences as 
long as they do not reduce enzyme activity to 
a relevant extent. However, the situation for 
topoisomerase II can be expected to be more 
critical: in principle a single molecule of a 
topoisomerase II-poison may trap a 
topoisomerase II protein at a step where 
DNA strands have been cleaved. This may 
lead to a single DNA double strand break, 
induce a single chromosome translocation 
and initiate a series of steps finally leading to 
neoplastic transformation. Of course the 
probability for neoplastic transformation 
resulting from a single DNA double strand 
break is extremely low, but it can be 
expected to be higher than zero. Thus, from a 
theoretical point of view topoisomerase II-
poisons can be expected to act by a non-
threshold mechanism. 
 
Recently, some alarming studies have been 
published, suggesting that exposure to low 
doses of topoisomerase II-poisons may 
indeed be relevant (Ross, 2000; Strick et al., 
2000; Alexander et al., 2001; McDonald et 
al., 2001): Approximately 80% of infants 
(younger than 1 year of age) with acute 
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myelogenous leukemia (AML) and acute 
lymphoblastic leukemia (ALL) have 
chromosome translocations involving the 
MLL gene. The above mentioned leukemias 
(AML) associated with etoposide 
chemotherapy manifested identical 
chromosomal translocations involving the 
MLL gene (Ross, 1998). The MLL cleavage 
site induced by etoposide colocalized with 
those observed in infant leukemia (Strick et 
al., 2000). In addition, molecular studies 
have suggested that leukemias in the first 
postnatal year have been initiated in utero. 
This led to the hypothesis that maternal 
exposure during pregnancy to environmental 
substances that inhibit topoisomerase II may 
cause development of leukemia in infants. 
This hypothesis has been examined in several 
studies (Ross, 2000; Strick et al., 2000; 
Alexander et al., 2001). Since topoisomerase 
II-inhibitors have been found in soy, wine, 
coffee, tea, cocao, pesticides, medications, 
specific fruits and vegetables, mothers of 
infant cases and matched controls were 
interviewed for potential exposure to 
topoisomerase II-inhibitors (Ross, 1998). An 
approximately 10-fold higher risk of infant 
AML with increasing maternal consumption 
of topoisomerase II-poison containing foods 
was reported in this study. Based on 20 
bioflavonoids tested, Strick et al. (2000) 
identified a common structure essential for 
topoisomerase II-induced DNA cleavage, 
suggesting that maternal ingestion of 
bioflavonoids induce MLL breaks leading to 
infant leukemia in utero. In addition, at least 
some bioflavonoids that act as topoisomerase 
II-poisons have been reported to be able to 
cross the rat placenta and reach fetal tissues 
(Schroder-van der Elst et al., 1998; Degen et 
al., 2002). In addition, the incidence of infant 
leukemia is almost 2-fold higher in several 
Asian cities, for example Hong Kong or 
Osaka, than in Western countries. This 
difference might be explained by the high 
food intake of bioflavonoids in many regions 
of Asia, especially by consumption of 
soybeans and soybean products (Strick et al., 
2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 2: Enzymatic action of topoisomerase II. The “classical” topoisomerase II-poisons act by
trapping the G-strand-enzyme intermediate (step F. in this figure), thus, blocking religation and
enzyme release, leaving the DNA with a permanent double strand break.  
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The observation that topoisomerase II 
associated chromosomal aberrations occur in 
infant leukemia leads to the question whether 
MLL-breaks induced by topoisomerase II-
poisons are important also for leukemias of 
adults. However, MLL abnormalities in adult 
leukemia that is not associated with 
topoisomerase II-therapy are less frequent 
than 5 % in contrast to approximately 80 % 
in infant leukemia. In addition no 
epidemiological data support a central role of 
diet in pathogenesis of adult leukemia. An 
explanation might be differences in the 
number of proliferating cells between adult 
and fetal bone marrow. It is known that the 
alpha isoform of topoisomerase II is 
expressed at higher levels in proliferation 
compared to quiescent cells. Due to the 
periods of rapid cell turnover it is likely that 
fetal tissues may be more susceptible to 
dietary topoisomerase II-poisons than adult 
tissues. 
 
It should be considered that a large number 
of studies has reported health benefits of 
bioflavonoids. Several epidemiological 
studies of human cancers, including prostate, 
colon and lung, reported a decreased risk 
associated with consumption of foods 
containing high levels of flavonoids. It has 
been hypothesized that high plasma 
concentrations of isoflavones could act like 
natural chemotherapeutic agents (Strick et 
al., 2000; Record et al., 1997). The example 
of topoisomerase II-poisons shows that the 
same substances may be beneficial or 
harmful probably depending on target cell 
types and their proliferation status during 
exposure. 
 
In conclusion, strong evidence has been 
presented that dietary topoisomerase II-
poisons may contribute to infant leukemia. If 
these observations can be confirmed by 
independent groups, soy products and other 
foods containing high levels of 
topoisomerase II-poisons should not be 
consumed during pregnancy. 
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